Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

276
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
276
Guidelines and Strategies for Safe Computer Charting01:18

Guidelines and Strategies for Safe Computer Charting

2.7K
The guidelines and strategies provided by the American Nurses Association (ANA) and the Canadian Nurses Association (CNA) offer essential principles for ensuring safe and secure computer charting systems in healthcare settings. Let's break down each recommendation:
Maintain Confidentiality and Security:
2.7K
Design Example: Calculating Safe Diameter for Wind-Exposed Disc01:17

Design Example: Calculating Safe Diameter for Wind-Exposed Disc

359
Assessing safety in wind-exposed installations is crucial to preventing potential failures. This example explores the calculation and design adjustments needed to mount a circular disc on a building facade, where wind forces are a primary concern. A 4-meter diameter disc was initially designed as an aesthetic feature facing winds at a velocity of 25 meters per second, with an air density of 1.25 kilograms per cubic meter. Given these conditions, the drag force on the disc was determined using...
359
Conformity01:20

Conformity

48.2K
Conformity is the change in a person’s behavior to go along with the group, even if that person does not agree with the group.
48.2K
Obedience01:08

Obedience

35.6K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.6K
Osmoregulation in Insects01:47

Osmoregulation in Insects

17.6K
Malpighian tubules are specialized structures found in the digestive systems of many arthropods, including most insects, that handle excretion and osmoregulation. The tubules are typically arranged in pairs and have a convoluted structure that increases their surface area.
17.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

PARP Inhibitors in Metastatic Castrate-Resistant Prostate Cancer.

JAMA network open·2025
Same author

Mitigating the Impact of Drug Shortages in Oncology: Lessons Learned From the 2023 Shortages of Carboplatin and Cisplatin.

Cancer journal (Sudbury, Mass.)·2025
Same author

Cancer Drugs and United States Tariffs: Attention Must Be Paid.

Cancer journal (Sudbury, Mass.)·2025
Same author

Fit4Surgery: A pilot randomized controlled trial to assess the feasibility of prehabilitation prior to debulking surgery for ovarian cancer.

Gynecologic oncology·2025
Same author

Abrupt fluoroquinolone-associated suicides: a SONAR report from North America, Europe, Australia, and Asia.

European journal of internal medicine·2025
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Related Experiment Video

Updated: Feb 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Biosimilars: Are They Really Safe?

June M McKoy1, Frank J Giles2

  • 1Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, IL, USA.

Cancer Treatment and Research
|December 16, 2018
PubMed
Summary
This summary is machine-generated.

The increasing availability of cancer biosimilars improves patient access and care. Regulatory approaches vary, necessitating attention to biosimilar safety, cost savings, and funding for innovative anticancer therapies.

Keywords:
Adverse eventsBiosimilarsCancerRegulatory approval

More Related Videos

External Cephalic Version: Is it an Effective and Safe Procedure?
08:49

External Cephalic Version: Is it an Effective and Safe Procedure?

Published on: June 6, 2020

15.8K
A Protocol for Safe Lithiation Reactions Using Organolithium Reagents
09:45

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents

Published on: November 12, 2016

32.0K

Related Experiment Videos

Last Updated: Feb 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
External Cephalic Version: Is it an Effective and Safe Procedure?
08:49

External Cephalic Version: Is it an Effective and Safe Procedure?

Published on: June 6, 2020

15.8K
A Protocol for Safe Lithiation Reactions Using Organolithium Reagents
09:45

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents

Published on: November 12, 2016

32.0K

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Regulatory Science

Background:

  • Biosimilars offer potential for improved cancer care access and cost savings.
  • Regulatory frameworks for biosimilars are evolving across major agencies.
  • Balancing biosimilar adoption with innovation in cancer therapy is crucial.

Purpose of the Study:

  • To discuss the implications of increasing biosimilar availability in oncology.
  • To examine the evolving regulatory landscape for biosimilars.
  • To highlight key considerations for biosimilar safety, cost-effectiveness, and research funding.

Main Methods:

  • Literature review of biosimilar regulatory policies.
  • Analysis of economic impacts of biosimilars in cancer treatment.
  • Discussion of safety profiles and pharmacoeconomic considerations.

Main Results:

  • Biosimilars are expanding access to cancer treatments.
  • Regulatory agencies employ diverse strategies for biosimilar approval and oversight.
  • Optimizing biosimilar integration requires careful attention to safety, cost, and research incentives.

Conclusions:

  • Increased biosimilar availability is vital for accessible and optimal cancer care.
  • Harmonized regulatory approaches and clear guidelines are needed.
  • Strategic planning is essential to leverage biosimilars for cost savings while sustaining innovation in oncology drug development.